{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_001",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:be1e4cc06ee70d8ef90c64ed406e8a8c486402df4ef0568727830a08f1374a30",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:01.181814",
  "content": "## 2024-03-04 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 45\n- Active: 45\n- Screen Failures Cumulative: 1\n- Withdrawals Cumulative: 0\n\n### Enrollment By Dose Group\n- Low Dose: 12\n- Mid Dose: 10\n- High Dose: 12\n- Placebo: 11\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 20.2\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 14.0\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 40.3\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC per 10^6) Mean: 64.0\n- CD4 Response (SFC per 10^6) SD: 15.0\n- CD8 Response (SFC per 10^6) Mean: 38.0\n- CD8 Response (SFC per 10^6) SD: 11.0\n- Seroconversion Percentage: 9.0\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 38.6\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 20.5\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 70.7\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC per 10^6) Mean: 104.0\n- CD4 Response (SFC per 10^6) SD: 24.0\n- CD8 Response (SFC per 10^6) Mean: 73.0\n- CD8 Response (SFC per 10^6) SD: 18.0\n- Seroconversion Percentage: 16.0\n\n#### High Dose\n- IgG Titer (GMU) Mean: 51.7\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 30.0\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 91.9\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC per 10^6) Mean: 134.0\n- CD4 Response (SFC per 10^6) SD: 33.0\n- CD8 Response (SFC per 10^6) Mean: 89.0\n- CD8 Response (SFC per 10^6) SD: 24.0\n- Seroconversion Percentage: 26.9\n\n#### Placebo\n- IgG Titer (GMU) Mean: 1.8\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 3.8\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 4.0\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC per 10^6) Mean: 5.0\n- CD4 Response (SFC per 10^6) SD: 3.0\n- CD8 Response (SFC per 10^6) Mean: 3.0\n- CD8 Response (SFC per 10^6) SD: 2.0\n- Seroconversion Percentage: 1.9\n\n### Injection Site Reactions\n- Pain Percentage: 62.5\n- Erythema Percentage: 23.4\n- Swelling Percentage: 8.3\n- Induration Percentage: 9.7\n- Mean Pain Duration (Hours): 46.1\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.8\n- Fatigue Percentage: 20.1\n- Myalgia Percentage: 20.3\n- Headache Percentage: 16.0\n- Chills Percentage: 6.3\n\n### Safety Labs\n- WBC (K) Mean: 7.5\n- WBC (K) SD: 1.2\n- Lymphocyte Percentage Mean: 30.5\n- Lymphocyte Percentage SD: 7.3\n- Neutrophil Percentage Mean: 53.9\n- Neutrophil Percentage SD: 9.7\n- Platelets (K) Mean: 222\n- Platelets (K) SD: 43\n- CRP (mg/L) Mean: 6.4\n- CRP (mg/L) SD: 1.5\n- Hemoglobin (g/dL) Mean: 14.1\n- Hemoglobin (g/dL) SD: 0.9\n\n### Adverse Events\n- AE ID: VI-AE-0187, Description: arthralgia, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0156, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Site 05 monitoring visit, 2 minor findings\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n- Serum sample aliquoting completed for 14 subjects\n\n### Notes\n- Week 1: Immunogenicity assessments on schedule. 45 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 1,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}